COVID-19 and SARS-CoV-2 Variants: Current Challenges and Health Concern

Abstract

The ongoing coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China, was triggered and unfolded quickly throughout the globe by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The new virus, transmitted primarily through inhalation or contact with infected droplets, seems very contagious and pathogenic, with an incubation period varying from 2 to 14 days. The epidemic is an ongoing public health problem that challenges the present global health system. A worldwide social and economic stress has been observed. The transitional source of origin and its transport to humans is unknown, but speedy human transportation has been accepted extensively. The typical clinical symptoms of COVID-19 are almost like colds. With case fatality rates varying from 2 to 3 percent, a small number of patients may experience serious health problems or even die. To date, there is a limited number of antiviral agents or vaccines for the treatment of COVID-19. The occurrence and pathogenicity of COVID-19 infection are outlined and comparatively analyzed, given the outbreak’s urgency. The recent developments in diagnostics, treatment, and marketed vaccine are discussed to deal with this viral outbreak. Now the scientist is concerned about the appearance of several variants over the globe and the efficacy of the vaccine against these variants. There is a need for consistent monitoring of the virus epidemiology and surveillance of the ongoing variant and related disease severity.

Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France

“…SARS-CoV-2 is able to rapidly genetically diversify and can spread internationally through travellers and cause successive outbreaks. SARS-CoV-2 variants cause the COVID-19 disease with different clinical manifestations, even in populations who have previously been exposed to original viruses ( Zeyaullah et al, 2021 ; SeyedAlinaghi et al, 2021 ; Gautret et al, 2021 ). In this study, we compared the demographics, clinical profile, and outcomes of patients infected with different variants that circulated or continue to circulate in the Marseille area, where three major phases have occurred until June 2021.…”

COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions

“…Current research indicates that antibodies produced by vaccines administered to indigenous people respond to these variants; however, more evidence and research is required to confirm this. In various studies, the mutations or their combinations showed diminished neutralizing activity of serum from mRNA-vaccinated people (Diamond et al, 2021;Zeyaullah et al, 2021).…”

El enigma del coronavirus – Covid-19 durante el Bicentenario de la Independencia del Perú – El síndrome poscovid – Las vacunas – La gestante

“…A principios de 2020, apareció una mutación D614G en el gen que codifica la proteína spike del SARS-CoV-2. La mutación D614G sustituyó gradualmente a la cepa original de SARS-CoV-2 descubierta en China y se convirtió en el tipo dominante del virus que circula en todo el mundo (10) . Hay pruebas emergentes de que la variante B.1.1.7 (Alpha) observada por primera vez en el Reino Unido es más infecciosa que las variantes anteriores y puede ser más virulenta (11) .…”